164 related articles for article (PubMed ID: 18766969)
1. Efficacy and safety of intrathecal liposomal cytarabine for the treatment of meningeal relapse in acute lymphoblastic leukemia: experience of two pediatric institutions.
Parasole R; Menna G; Marra N; Petruzziello F; Locatelli F; Mangione A; Misuraca A; Buffardi S; Di Cesare-Merlone A; Poggi V
Leuk Lymphoma; 2008 Aug; 49(8):1553-9. PubMed ID: 18766969
[TBL] [Abstract][Full Text] [Related]
2. Compassionate use of intrathecal depot liposomal cytarabine as treatment of central nervous system involvement in acute leukemia: report of 6 cases.
Sancho JM; Ribera JM; Romero MJ; Martín-Reina V; Giraldo P; Ruiz E
Haematologica; 2006 Mar; 91(3):ECR02. PubMed ID: 16533729
[TBL] [Abstract][Full Text] [Related]
3. Toxicity and efficacy of intrathecal liposomal cytarabine in children with leukemia/lymphoma relapsing in the central nervous system: a retrospective multicenter study.
Parasole R; Petruzziello F; Messina C; Barisone E; Pession A; Locatelli F; Micalizzi C; Cesaro S; Testi AM; De Matteo A; Varotto S; Berger M; Morello W; Menna G; Poggi V
Leuk Lymphoma; 2015 Mar; 56(3):650-5. PubMed ID: 24882262
[TBL] [Abstract][Full Text] [Related]
4. Intraventricular concentration times time (C x T) methotrexate and cytarabine for patients with recurrent meningeal leukemia and lymphoma.
Moser AM; Adamson PC; Gillespie AJ; Poplack DG; Balis FM
Cancer; 1999 Jan; 85(2):511-6. PubMed ID: 10023723
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia.
Bassan R; Masciulli A; Intermesoli T; Audisio E; Rossi G; Pogliani EM; Cassibba V; Mattei D; Romani C; Cortelezzi A; Corti C; Scattolin AM; Spinelli O; Tosi M; Parolini M; Marmont F; Borlenghi E; Fumagalli M; Cortelazzo S; Gallamini A; Marfisi RM; Oldani E; Rambaldi A
Haematologica; 2015 Jun; 100(6):786-93. PubMed ID: 25749825
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Toxicity of Intrathecal Liposomal Cytarabine in First-line Therapy of Childhood Acute Lymphoblastic Leukemia.
Levinsen M; Harila-Saari A; Grell K; Jonsson OG; Taskinen M; Abrahamsson J; Vettenranta K; Åsberg A; Risteli J; Heldrup J; Schmiegelow K
J Pediatr Hematol Oncol; 2016 Nov; 38(8):602-609. PubMed ID: 27571129
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of intrathecal liposomal cytarabine as central nervous system prophylaxis in patients with acute lymphoblastic leukemia.
Valentin A; Troppan K; Pfeilstöcker M; Nösslinger T; Linkesch W; Neumeister P
Leuk Lymphoma; 2014 Aug; 55(8):1739-42. PubMed ID: 24138308
[TBL] [Abstract][Full Text] [Related]
8. Intrathecal liposomal cytarabine and leptomeningeal medulloblastoma relapse: a valuable therapeutic option.
Mastronuzzi A; Del Bufalo F; Iacono A; Secco DE; Serra A; Colafati GS; DE Ioris MA; Corsetti T
Anticancer Res; 2013 Aug; 33(8):3515-8. PubMed ID: 23898128
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis.
Bomgaars L; Geyer JR; Franklin J; Dahl G; Park J; Winick NJ; Klenke R; Berg SL; Blaney SM
J Clin Oncol; 2004 Oct; 22(19):3916-21. PubMed ID: 15459213
[TBL] [Abstract][Full Text] [Related]
10. Liposomal cytarabine (DepoCyte) for the treatment of neoplastic meningitis.
Rueda Domínguez A; Olmos Hidalgo D; Viciana Garrido R; Torres Sánchez E
Clin Transl Oncol; 2005 Jul; 7(6):232-8. PubMed ID: 16131445
[TBL] [Abstract][Full Text] [Related]
11. Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis.
Benesch M; Sovinz P; Krammer B; Lackner H; Mann G; Schwinger W; Gadner H; Urban C
J Pediatr Hematol Oncol; 2007 Apr; 29(4):222-6. PubMed ID: 17414563
[TBL] [Abstract][Full Text] [Related]
12. Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma.
Gökbuget N; Hartog CM; Bassan R; Derigs HG; Dombret H; Greil R; Hernández-Rivas JM; Huguet F; Intermesoli T; Jourdan E; Junghanss C; Leimer L; Moreno MJ; Reichle A; Ribera J; Schmid M; Serve H; Stelljes M; Stuhlmann R; Hoelzer D;
Haematologica; 2011 Feb; 96(2):238-44. PubMed ID: 20952517
[TBL] [Abstract][Full Text] [Related]
13. Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study.
Benesch M; Siegler N; Hoff Kv; Lassay L; Kropshofer G; Müller H; Sommer C; Rutkowski S; Fleischhack G; Urban C
Anticancer Drugs; 2009 Oct; 20(9):794-9. PubMed ID: 19617818
[TBL] [Abstract][Full Text] [Related]
14. Clinical experience using intrathecal liposomal cytarabine to manage neoplastic meningitis in three patients with acute promyelocytic leukemia.
Duarte RF; Arnan M; Sánchez-Ortega I; de Llano MP; Abellán PF
Leuk Res; 2011 Jul; 35(7):e128-30. PubMed ID: 21501870
[No Abstract] [Full Text] [Related]
15. Intrathecal liposomal cytarabine for prevention of meningeal disease in patients with acute lymphocytic leukemia and high-grade lymphoma.
McClune B; Buadi FK; Aslam N; Przepiorka D
Leuk Lymphoma; 2007 Sep; 48(9):1849-51. PubMed ID: 17786723
[No Abstract] [Full Text] [Related]
16. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
[TBL] [Abstract][Full Text] [Related]
17. Intrathecal liposomal cytarabine (lipoCIT) administration in patients with leukemic or lymphomatous meningitis: efficacy and long-term safety in a single institution.
Brion A; Legrand F; Larosa F; Schillinger F; Garnache-Ottou F; Helias P; Fontan J; Heczko M; Delaby P; Daguindau E; Vuillier J; Chauchet A; Deconinck E
Invest New Drugs; 2012 Aug; 30(4):1697-702. PubMed ID: 21229289
[TBL] [Abstract][Full Text] [Related]
18. [Cerebrospinal fluid examination after liposomal cytarabine intrathecal injection].
Guillaume C; Vegas H; Pastuszka A; Le Brun C; Lanotte P
Ann Biol Clin (Paris); 2018 Oct; 76(5):568-570. PubMed ID: 30154068
[TBL] [Abstract][Full Text] [Related]
19. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
[TBL] [Abstract][Full Text] [Related]
20. Practice of central nervous system prophylaxis and treatment in acute leukemias in Spain. Prospective registry study.
Sancho JM; Morgades M; Arranz R; Fernández-Abellán P; Deben G; Alonso N; Blanes M; Rodríguez MJ; Nicolás C; Sánchez E; Fernández de Sevilla A; Conde E; Ribera JM;
Med Clin (Barc); 2008 Oct; 131(11):401-5. PubMed ID: 18928719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
